ATLAS fair value
ATLAS has no fair value for this stock today.
Orchid Pharma share price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · National Stock Exchange of India · India
Prices as of Oct 26, 2026 · INR
ATLAS has no fair value for this stock today.
49%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives Orchid Pharma a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₹752.65 and ₹884.01; in 9 out of 10, between ₹652.62 and ₹1,020. Estimated annual volatility is 46%.
ATLAS does not publish a fair value for ORCHPHARMA.NSE right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks ORCHPHARMA.NSE has traded between ₹480.00 and ₹1,144. Today it is 28.4% below that high and 70% above its low.
On the business: net margin is 3.5%; it trades at 555.0 times earnings.
Its beta is 0.49: it tends to move less than the market.
Orchid Pharma Ltd., a key player in the pharmaceutical industry, specializes in the manufacturing and export of bulk drugs, or Active Pharmaceutical Ingredients (APIs).
Want to see everything about Orchid Pharma?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
Orchid Pharma Ltd., a key player in the pharmaceutical industry, specializes in the manufacturing and export of bulk drugs, or Active Pharmaceutical Ingredients (APIs).
49%: close to a coin flip. In half of the simulated outcomes, ORCHPHARMA.NSE ends the month between ₹752.65 and ₹884.01.
Orchid Pharma's market capitalization is ₹45.3B. Its price-to-earnings (P/E) ratio is 555.0: you pay ₹555.0 for each ₹1.00 of yearly earnings.
Yes. ORCHPHARMA.NSE's current dividend yield is 1.34% at today's price (₹818.35).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy